Clinical Trial Update: A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sipuleucel-T with enzalutamide in metastatic castration-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: Dendreon | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-09-25